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Duchenne muscular dystrophy (DMD) is the most common childhood muscle wasting 
disease.  DMD sufferers rarely survive past their mid-twenties succumbing to 
respiratory or heart failure.  Skeletal and heart muscle pathology in DMD are caused 
by mutations in the dystrophin gene.  Gene therapy strategies to restore dystrophin 
expression bring the hope of a cure for DMD.  Unfortunately, treatment of the heart 
remains largely unexplored.  A critical question for heart gene therapy is the 
percentage of cells which must be repaired.  We have previously shown that 
expressing a mosaic pattern of dystrophin in 50% of cardiomyocytes prevents heart 
disease (Bostick et al 2008 Cir Res102:121-130).  A surprising finding from this 
study was up-regulation of a dystrophin homolog, utrophin, strictly in dystrophin-
negative cardiomyocytes.  This finding implicates a role for utrophin in modulating 
DMD heart disease.  To answer this question, we developed a mouse model 
expressing 50% mosaic dystrophin in the heart with utrophin expression knocked out.  
We then analyzed cardiac physiology, anatomical/histological morphology and 
dystrophin/utrophin expression.  We found that 50% mosaic dystrophin in the 
absence of utrophin normalized electrocardiographic parameters of the heart.  Left 
ventricular catheterization revealed normal stroke volume, cardiac output and markers 
of contractility.  Additionally, dobutamine stress response and mouse survival were 
normalized.  Interestingly, utrophin knockout mice exhibited increased end-diastolic 
and end-systolic volumes.  Our findings support the previous hypothesis that 50% 
mosaic dystrophin expression in the heart ameliorates DMD heart disease.  However, 
the increased end-diastolic and end-systolic volumes indicate a potential role for 
utrophin in strengthening the integrity of the heart. 
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